EVT planning to restart EndoVascular Grafting System trials by year-end.
This article was originally published in The Gray Sheet
Executive Summary
ENDOVASCULAR TECHNOLOGIES ENDOVASCULAR GRAFTING SYSTEM CLINICALS are expected to recommence before the end of 1995, company President and CEO Jim Fitzsimmons said at a May 16 session of the Alex. Brown & Sons Health Care Seminar in Baltimore. Earlier this year, the privately held company voluntarily suspended two trials following discovery of breaks in the attachment component of the grafting system ("The Gray Sheet" Feb. 27, p. 13). The suspended studies -- a Phase II trial of the EndoGraft tube vascular graft implant and a Phase I study of the bifurcated EndoGraft -- were evaluating the systems in the treatment of abdominal aortic aneurysms.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.